jmo only... think it could see intial moves to .20's+++
after all, the merger would solidify XTend Med's ownership in BioHarp... something it only has a partnership if any right now, but not the kit and kaboodle....
With all the medical breakthru news on this device and the fact that other countries are interested in it, will make this an instant need to have stock.
Those that keep their shares for a while will see huge returns on their investment.
I am thinking .25cents or more when the deal is done. Probbaly more. But thats not important. I am holding for at least 1.00pps on most of my shares. This device has way too much potential for me to sell my shares at .25 cents. I see dollars pps potential early next year.
Market Data 
Markets 
AI
